MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1

Authors

  • Zhuo-Yuan Lin,

    1. Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou, China
    2. Department of Urology Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China
    Search for more papers by this author
    • Z.-Y.L., Y.-Q.H., and Y.-Q.Z. contributed equally to this article.

  • Ya-Qiang Huang,

    1. Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou, China
    Search for more papers by this author
    • Z.-Y.L., Y.-Q.H., and Y.-Q.Z. contributed equally to this article.

  • Yan-Qiong Zhang,

    1. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China
    Search for more papers by this author
    • Z.-Y.L., Y.-Q.H., and Y.-Q.Z. contributed equally to this article.

  • Zhao-Dong Han,

    1. Department of Urology Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China
    Search for more papers by this author
  • Hui-Chan He,

    1. Department of Urology Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China
    Search for more papers by this author
  • Xiao-Hui Ling,

    1. Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou, China
    2. Department of Urology Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China
    Search for more papers by this author
  • Xin Fu,

    1. Department of Urology Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China
    Search for more papers by this author
  • Qi-Shan Dai,

    1. Department of Urology Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China
    Search for more papers by this author
  • Chao Cai,

    1. Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou, China
    2. Department of Urology Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China
    Search for more papers by this author
  • Jia-Hong Chen,

    1. Department of Urology Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China
    Search for more papers by this author
  • Yu-Xiang Liang,

    1. Department of Urology Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China
    Search for more papers by this author
  • Fu-Neng Jiang,

    1. Department of Urology Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China
    Search for more papers by this author
  • Wei-De Zhong,

    Corresponding author
    1. Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou, China
    2. Department of Urology Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China
    3. Urology Key Laboratory of Guangdong Province, Guangzhou Medical University, Guangzhou, China
    • Correspondence to: Wei-De Zhong, Department of Urology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China, Tel: +8620-81048312; Fax: +8620-83373322, E-mail: zhongwd2009@live.cn

    Search for more papers by this author
  • Fen Wang,

    1. Center for Cancer and Stem Cell Biology Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, TX
    Search for more papers by this author
  • Chin-Lee Wu

    1. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
    2. Department of Urology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
    Search for more papers by this author

Abstract

Our previous microarray data showed that microRNA-224 (miR-224) was downregulated in human prostate cancer (PCa) tissues compared with adjacent benign tissues. However, the underlying mechanisms by which miR-224 is involved in PCa remain unclear. In this study, we identified TRIB1 as a target gene of miR-224. Forced expression of miR-224 suppressed PCa cell proliferation, invasion and migration, and promoted cell apoptosis by downregulating TRIB1. Moreover, the expression level of miR-224 in PCa tissues was negatively correlated with that of TRIB1. miR-224 downregulation was frequently found in PCa tissues with metastasis, higher PSA level and clinical stage, whereas TRIB1 upregulation was significantly associated with metastasis. Both miR-224 downregulation and TRIB1 upregulation were significantly associated with poor biochemical recurrence-free survival of patients with PCa. In conclusion, these findings reveal that the aberrant expression of miR-224 and TRIB1 may promote PCa progression and have potentials to serve as novel biomarkers for PCa prognosis.

Ancillary